Geron claims embryonic stem cell breakthrough for MI therapy
This article was originally published in Clinica
Executive Summary
A recent study assessing the human embryonic stem cell (hESC)-derived cardiomyocytes developed by Geron has been hailed as a landmark by the firm, after its results indicated that it could lead to an off-the-shelf heart attack therapy - the first of its kind.